Back

Dysregulation of FicD AMPylation causes diabetes by disrupting pancreatic endocrine homeostasis

Casey, A. K.; Stewart, N. M. S.; Zaidi, N.; Gray, H. F.; Fields, H. A.; Sakurai, M.; Pinzon-Arteaga, C. A.; Evers, B. M.; Wu, J.; Orth, K.

2024-10-26 physiology
10.1101/2024.10.25.620287 bioRxiv
Show abstract

Bi-functional enzyme FicD regulates the endoplasmic reticulum chaperone BiP using AMPylation and deAMPylation during ER homeostasis and stress, respectively. Human FicD with an arginine-to-serine mutation disrupts FicD deAMPylation activity resulting in severe neonatal diabetes. We generated the FicDR371S mutation in mice to create a pre-clinical murine model for neonatal diabetes. We observed elevated BiP AMPylation levels across multiple tissues and signature markers for diabetes including glucose intolerance and reduced serum insulin levels. While the pancreas of FicDR371S mice appeared normal at birth, adult FicDR371S mice displayed disturbed pancreatic islet organization that progressed with age. FicDR371S mice provide a preclinical mouse model for the study of UPR associated diabetes and demonstrate the essentiality of FicD for tissue resilience.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.